Zimmer Biomet’s (ZBH) Buy Rating Reiterated at Argus

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating reaffirmed by research analysts at Argus in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Argus‘s target price would indicate a potential upside of 27.20% from the stock’s current price.

ZBH has been the subject of several other research reports. Sanford C. Bernstein increased their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Barclays raised Zimmer Biomet to a “hold” rating in a research note on Wednesday, October 7th. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Citigroup restated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, October 5th. Finally, Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $104.47.

Zimmer Biomet Stock Performance

ZBH stock traded up $3.41 during trading on Thursday, reaching $98.27. The stock had a trading volume of 516,622 shares, compared to its average volume of 2,223,891. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $104.15. The stock’s 50 day moving average is $95.18 and its two-hundred day moving average is $91.41. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a market cap of $18.74 billion, a PE ratio of 23.90, a PEG ratio of 1.81 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the business posted $2.07 earnings per share. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current year.

Insider Transactions at Zimmer Biomet

In other news, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Citizens National Bank Trust Department raised its holdings in shares of Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 141 shares during the last quarter. Leonteq Securities AG lifted its holdings in shares of Zimmer Biomet by 5.3% in the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after acquiring an additional 153 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Zimmer Biomet by 1.6% in the 2nd quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock valued at $962,000 after buying an additional 175 shares during the period. Corbyn Investment Management Inc. MD raised its holdings in shares of Zimmer Biomet by 0.5% in the 1st quarter. Corbyn Investment Management Inc. MD now owns 34,050 shares of the medical equipment provider’s stock valued at $3,079,000 after buying an additional 183 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Zimmer Biomet by 32.1% in the first quarter. Parallel Advisors LLC now owns 798 shares of the medical equipment provider’s stock valued at $72,000 after acquiring an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.